Omada Health
Virtual chronic-care platform with weight health, GLP-1 companion programs, diabetes, hypertension, MSK, and behavior-change support. Strong B2B distribution with integrated care journeys.
Access model
Mostly through employers, health plans, and health systems
Editorial note
Coverage and cost
Generally yes via employer/health-plan benefit
Not publicly disclosed; sponsor-specific
No public emphasis; public positioning centers on behavior change plus FDA-approved GLP-1 support
Market signals
Evidence and positioning
Public 2026 outcomes: 18.4% average 1-year weight loss for members persistent on GLP-1s, 13.1% for members who discontinued before 1 year, and 16.3% across all members in the program. Omada also published post-discontinuation maintenance analyses.
This is the lower dB's current read on Omada Health's pricing posture, insurance story, medication posture, and evidence signaling.
Source References
5 public references used in this profile. Links open in a new tab for quick verification.
Pricing, insurance coverage, medication availability, and eligibility can change quickly. Verify current details directly with the provider before starting or switching care.